Dr. Farago is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-4000- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014- Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2010
Harvard Medical SchoolClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Start of enrollment: 2015 Oct 13
- Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Publications & Presentations
PubMed
- 24 citationsCombination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomi...Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F Smit, Alberto Chiappori, Maria Eugenia Olmedo, Ildiko Horvath, Chr...> ;The Lancet. Respiratory Medicine. 2023 Jan 1
- 30 citationsDiscovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.Andreas Weiss, Edwige Lorthiois, Louise Barys, Kim S Beyer, Claudio Bomio-Confaglia, Heather Burks, Xueying Chen, Xiaoming Cui, Ruben de Kanter, Lekshmi Dharmarajan, C...> ;Cancer Discovery. 2022 Jun 2
- 8 citationsTranslesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.Marcello Stanzione, Jun Zhong, Edmond Wong, Thomas J LaSalle, Jillian F Wise, Antoine Simoneau, David T Myers, Sarah Phat, Moshe Sade-Feldman, Michael S Lawrence, M Ky...> ;Science Advances. 2022 May 13
- Join now to see all
Lectures
- ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Combining Forces in Small Cell Lung CancerNovember 21st, 2019
Potential New Treatment Strategy for Relapsed SCLCSeptember 11th, 2019
PARP Inhibitor Combination Shows Activity in Small Cell Lung CancerAugust 21st, 2019- Join now to see all
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
